PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930035
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930035
Brain Tumor Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
Growth Factors of brain tumor drugs Market
The global brain tumor drugs market is witnessing steady growth driven by the rising incidence of brain cancer, advancements in diagnosis, and increasing investment in drug development. In 2025, the global market was valued at USD 2.29 billion. It is projected to grow to USD 2.55 billion in 2026 and further reach USD 5.2 billion by 2034, registering a CAGR of 9.30% during the forecast period (2026-2034).
North America dominated the market with a 43.38% share in 2025, supported by strong reimbursement policies, advanced healthcare infrastructure, and a robust pipeline of oncology drugs. The U.S. brain tumor drugs market is expected to grow significantly, reaching USD 1.47 billion by 2030.
Brain tumors are abnormal masses of tissue caused by uncontrolled cell growth in the brain. They are classified into primary tumors, originating in the brain, and metastatic tumors, which spread from other organs. Primary tumors account for the majority of diagnosed cases globally.
Market Drivers
Rising Prevalence of Brain Cancer
The increasing prevalence of brain tumors worldwide is a major factor driving market growth. Lifestyle changes, smoking, aging populations, exposure to radiation, and environmental factors have contributed to rising cancer incidence. Brain tumors account for nearly 1-2% of total cancer cases, yet they exhibit a high mortality rate.
According to the International Agency for Research on Cancer, global brain cancer incidence is expected to rise from 308,102 cases in 2024 to 415,183 cases by 2040. Increasing diagnosis and treatment rates, particularly in North America and Asia Pacific, are boosting the demand for brain tumor drugs.
Strong Pipeline and R&D Investments
The market is further supported by a strong pipeline of investigational drugs. By 2025, more than 150 brain tumor drug candidates were under clinical development. Governments and research organizations are actively funding brain cancer research to address unmet medical needs. For instance, in October 2022, the Australian government allocated USD 4.0 million to support brain cancer research initiatives.
Market Trends
Advancements in Diagnosis and Personalized Medicine
Early diagnosis of brain tumors remains challenging due to the blood-brain barrier, which limits drug delivery. However, advancements in molecular diagnostics, liquid biopsy, and genetic biomarker analysis are improving early detection and treatment outcomes.
Innovations such as circulating tumor DNA analysis and blood-based diagnostic tests are gaining traction. In January 2023, Datar Cancer Genetics received U.S. FDA breakthrough designation for TriNetr-Glio, a liquid biopsy test for detecting malignant brain tumors. These advancements are expected to increase diagnosis rates and drug adoption.
COVID-19 Impact
The brain tumor drugs market was negatively impacted during the COVID-19 pandemic due to delayed diagnosis and treatment. According to the CDC, cancer incidence declined by 11% in 2024 compared to 2019, primarily due to reduced screenings. Major players also faced supply chain disruptions and revenue declines. For instance, F. Hoffmann-La Roche Ltd. reported a 29.4% decline in Avastin revenues in 2024. However, market recovery began as healthcare services resumed post-pandemic.
Market Segmentation Analysis
By Therapy
The market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.
The chemotherapy segment dominated the market with a 38.49% share in 2026, as it remains the first-line and adjuvant treatment for brain tumors.
Targeted therapy and immunotherapy segments are expected to grow rapidly due to increasing approvals, clinical collaborations, and advancements in precision medicine.
By Indication
Based on indication, the market includes glioma, meningioma, pituitary, and others.
The glioma segment led the market with a 41.24% share in 2026, driven by the high prevalence of malignant gliomas and increasing drug launches for glioblastoma treatment.
By Distribution Channel
The hospital pharmacy segment dominated the market with a 94.25% share in 2026, as these drugs require hospital-based administration and insurance reimbursement. Retail and online pharmacies are gradually expanding with increased outpatient treatment.
Regional Insights
- North America: Valued at USD 1.0 billion in 2025 and USD 1.1 billion in 2026, driven by FDA approvals and strong reimbursement.
- Europe: Held 26.83% market share in 2025, supported by orphan drug designations and regulatory support.
- Asia Pacific: Accounted for 18.98% share in 2025 and is expected to grow at the fastest CAGR due to rising awareness and improving diagnosis.
- Latin America and Middle East & Africa are expanding steadily due to improving healthcare infrastructure.
Competitive Landscape
The market is consolidated, with leading players such as F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Merck & Co., Amgen Inc., and Amneal Pharmaceuticals LLC. Strategic initiatives including acquisitions, FDA approvals, and pipeline expansion are strengthening market competition.
Conclusion
In conclusion, the global brain tumor drugs market is poised for consistent growth, expanding from USD 2.29 billion in 2025 to USD 5.2 billion by 2034. Rising brain cancer prevalence, strong drug pipelines, advancements in diagnostics, and increasing government support are driving market expansion. Despite challenges such as high treatment costs and limited reimbursement in developing regions, continuous innovation and regulatory approvals are expected to sustain long-term market growth.
Segmentation By Therapy
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Others
By Indication
- Pituitary
- Meningioma
- Glioma
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail & Online Pharmacy
By Region
- North America (By Therapy, By Indication, By Distribution Channel, and By Country)
- U.S. (By Indication)
- Canada (By Indication)
- Europe (By Therapy, By Indication, By Distribution Channel, and By Country)
- U.K. (By Indication)
- Germany (By Indication)
- France (By Indication)
- Italy (By Indication)
- Spain (By Indication)
- Rest of Europe (By Indication)
- Asia Pacific (By Therapy, By Indication, By Distribution Channel, and By Country)
- China (By Indication)
- Japan (By Indication)
- India (By Indication)
- Australia (By Indication)
- Southeast Asia (By Indication)
- Rest of Asia Pacific (By Indication)
- Latin America (By Therapy, By Indication, By Distribution Channel, and By Country)
- Brazil (By Indication)
- Mexico (By Indication)
- Rest of Latin America (By Indication)
- Middle East & Africa (By Therapy, By Indication, By Distribution Channel, and By Country)
- GCC (By Indication)
- South Africa (By Indication)
- Rest of Middle East & Africa (By Indication)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Incidence of Brain Cancer, Key Region, 2024/2025
- 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
- 4.3. Overview of the Regulatory Scenario by Key Region/Countries
- 4.4. New Product Launches by Key Players
- 4.5. Impact of COVID-19 on Brain Tumor Drugs Market
5. Global Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034
- 5.1. Market Analysis, Insights and Forecast - By Therapy
- 5.1.1. Targeted Therapy
- 5.1.2. Chemotherapy
- 5.1.3. Immunotherapy
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Pituitary Tumors
- 5.2.2. Meningioma
- 5.2.3. Glioblastoma
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacy
- 5.3.2. Retail & Online Pharmacy
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034
- 6.1. Market Analysis, Insights and Forecast - By Therapy
- 6.1.1. Targeted Therapy
- 6.1.2. Chemotherapy
- 6.1.3. Immunotherapy
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Pituitary Tumors
- 6.2.2. Meningioma
- 6.2.3. Glioblastoma
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacy
- 6.3.2. Retail & Online Pharmacy
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.1.1. By Indication
- 6.4.2. Canada
- 6.4.2.1. By Indication
- 6.4.1. U.S.
7. Europe Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034
- 7.1. Market Analysis, Insights and Forecast - By Therapy
- 7.1.1. Targeted Therapy
- 7.1.2. Chemotherapy
- 7.1.3. Immunotherapy
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Pituitary Tumors
- 7.2.2. Meningioma
- 7.2.3. Glioblastoma
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacy
- 7.3.2. Retail & Online Pharmacy
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.4.1. Germany
- 7.4.1.1. By Indication
- 7.4.2. U.K.
- 7.4.2.1. By Indication
- 7.4.3. France
- 7.4.3.1. By Indication
- 7.4.4. Spain
- 7.4.4.1. By Indication
- 7.4.5. Italy
- 7.4.5.1. By Indication
- 7.4.6. Scandinavia
- 7.4.6.1. By Indication
- 7.4.7. Rest of Europe
- 7.4.7.1. By Indication
- 7.4.1. Germany
8. Asia Pacific Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034
- 8.1. Market Analysis, Insights and Forecast - By Therapy
- 8.1.1. Targeted Therapy
- 8.1.2. Chemotherapy
- 8.1.3. Immunotherapy
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Pituitary Tumors
- 8.2.2. Meningioma
- 8.2.3. Glioblastoma
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail & Online Pharmacy
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.4.1. Japan
- 8.4.1.1. By Indication
- 8.4.2. China
- 8.4.2.1. By Indication
- 8.4.3. India
- 8.4.3.1. By Indication
- 8.4.4. Australia
- 8.4.4.1. By Indication
- 8.4.5. Southeast Asia
- 8.4.5.1. By Indication
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Indication
- 8.4.1. Japan
9. Latin America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034
- 9.1. Market Analysis, Insights and Forecast - By Therapy
- 9.1.1. Targeted Therapy
- 9.1.2. Chemotherapy
- 9.1.3. Immunotherapy
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Pituitary Tumors
- 9.2.2. Meningioma
- 9.2.3. Glioblastoma
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail & Online Pharmacy
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Indication
- 9.4.2. Mexico
- 9.4.2.1. By Indication
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Indication
- 9.4.1. Brazil
10. Middle East & Africa Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034
- 10.1. Market Analysis, Insights and Forecast - By Therapy
- 10.1.1. Targeted Therapy
- 10.1.2. Chemotherapy
- 10.1.3. Immunotherapy
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1. Pituitary Tumors
- 10.2.2. Meningioma
- 10.2.3. Glioblastoma
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital Pharmacy
- 10.3.2. Retail & Online Pharmacy
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Indication
- 10.4.2. South Africa
- 10.4.2.1. By Indication
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Indication
- 10.4.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
- 11.2.1. Pfizer Inc.
- 11.2.1.1. Overview,
- 11.2.1.2. Product,
- 11.2.1.3. SWOT Analysis,
- 11.2.1.4. Recent Developments,
- 11.2.1.5. Strategies,
- 11.2.1.6. financials (Based on Availability)
- 11.2.2. F. Hoffmann-La Roche Ltd
- 11.2.2.1. Overview,
- 11.2.2.2. Product,
- 11.2.2.3. SWOT Analysis,
- 11.2.2.4. Recent Developments,
- 11.2.2.5. Strategies,
- 11.2.2.6. financials (Based on Availability)
- 11.2.3. Novartis AG
- 11.2.3.1. Overview,
- 11.2.3.2. Product,
- 11.2.3.3. SWOT Analysis,
- 11.2.3.4. Recent Developments,
- 11.2.3.5. Strategies,
- 11.2.3.6. financials (Based on Availability)
- 11.2.4. Merck & Co. Inc.
- 11.2.4.1. Overview,
- 11.2.4.2. Product,
- 11.2.4.3. SWOT Analysis,
- 11.2.4.4. Recent Developments,
- 11.2.4.5. Strategies,
- 11.2.4.6. financials (Based on Availability)
- 11.2.5. Amneal Pharmaceuticals LLC.
- 11.2.5.1. Overview,
- 11.2.5.2. Product,
- 11.2.5.3. SWOT Analysis,
- 11.2.5.4. Recent Developments,
- 11.2.5.5. Strategies,
- 11.2.5.6. financials (Based on Availability)
- 11.2.6. Amgen Inc.
- 11.2.6.1. Overview,
- 11.2.6.2. Product,
- 11.2.6.3. SWOT Analysis,
- 11.2.6.4. Recent Developments,
- 11.2.6.5. Strategies,
- 11.2.6.6. financials (Based on Availability)
- 11.2.7. NextSource Pharmaceuticals, LLC
- 11.2.7.1. Overview,
- 11.2.7.2. Product,
- 11.2.7.3. SWOT Analysis,
- 11.2.7.4. Recent Developments,
- 11.2.7.5. Strategies,
- 11.2.7.6. financials (Based on Availability)
- 11.2.8. Emcure Pharmaceuticals
- 11.2.8.1. Overview,
- 11.2.8.2. Product,
- 11.2.8.3. SWOT Analysis,
- 11.2.8.4. Recent Developments,
- 11.2.8.5. Strategies,
- 11.2.8.6. financials (Based on Availability)
- 11.2.1. Pfizer Inc.
List of Tables
- Table 1: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
- Table 2: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 3: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
- Table 4: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Region, 2025-2034
- Table 5: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
- Table 6: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 7: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
- Table 8: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country, 2025-2034
- Table 9: U.S. Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 10: Canada Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 11: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
- Table 12: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 13: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
- Table 14: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
- Table 15: Germany Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 16: U.K. Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 17: France Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 18: Italy Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 19: Spain Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 20: Scandinavia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 21: Rest of Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 22: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
- Table 23: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 24: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
- Table 25: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
- Table 26: Japan Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 27: India Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 28: China Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 29: Australia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 30: Southeast Asia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 31: Rest of Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 32: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
- Table 33: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 34: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
- Table 35: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
- Table 36: Brazil Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 37: Mexico Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 38: Rest of Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 39: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
- Table 40: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 41: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
- Table 42: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
- Table 43: GCC Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 44: South Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
- Table 45: Rest of Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
List of Figures
- Figure 1: Global Brain Tumor Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Brain Tumor Drugs Market Value Share (%), by Therapy, 2025 & 2034
- Figure 3: Global Brain Tumor Drugs Market Forecast (USD billion), by Targeted Therapy, 2025-2034
- Figure 4: Global Brain Tumor Drugs Market Forecast (USD billion), by Chemotherapy, 2025-2034
- Figure 5: Global Brain Tumor Drugs Market Forecast (USD billion), by Immunotherapy, 2025-2034
- Figure 6: Global Brain Tumor Drugs Market Forecast (USD billion), by Others, 2025-2034
- Figure 7: Global Brain Tumor Drugs Market Value Share (%), by Indication, 2025 & 2034
- Figure 8: Global Brain Tumor Drugs Market Forecast (USD billion), by Pituitary Tumors, 2025-2034
- Figure 9: Global Brain Tumor Drugs Market Forecast (USD billion), by Meningioma, 2025-2034
- Figure 10: Global Brain Tumor Drugs Market Forecast (USD billion), by Glioblastoma, 2025-2034
- Figure 11: Global Brain Tumor Drugs Market Forecast (USD billion), by Others, 2025-2034
- Figure 12: Global Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 13: Global Brain Tumor Drugs Market Forecast (USD billion), by Hospital Pharmacy, 2025-2034
- Figure 14: Global Brain Tumor Drugs Market Forecast (USD billion), by Retail & Online Pharmacy, 2025-2034
- Figure 15: Global Brain Tumor Drugs Market Value (USD billion), by Region, 2025 & 2034
- Figure 16: North America Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 17: North America Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
- Figure 18: North America Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 19: North America Brain Tumor Drugs Market Value Share (%), by Indication, 2025
- Figure 20: North America Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 21: North America Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 22: North America Brain Tumor Drugs Market Value (USD billion), By Country, 2025 & 2034
- Figure 23: North America Brain Tumor Drugs Market Value Share (%), By Country, 2025
- Figure 24: Europe Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 25: Europe Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
- Figure 26: Europe Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 27: Europe Brain Tumor Drugs Market Value Share (%), by Indication, 2025
- Figure 28: Europe Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 29: Europe Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 30: Europe Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 33: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
- Figure 34: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 35: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Indication, 2025
- Figure 36: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 37: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 38: Asia Pacific Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 39: Asia Pacific Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 40: Latin America Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 41: Latin America Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
- Figure 42: Latin America Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 43: Latin America Brain Tumor Drugs Market Value Share (%), by Indication, 2025
- Figure 44: Latin America Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 45: Latin America Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 46: Latin America Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 47: Latin America Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 48: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 49: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
- Figure 50: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 51: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Indication, 2025
- Figure 52: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 53: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 54: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 55: Middle East & Africa Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Global Brain Tumor Drugs Market Share (%), By Company, 2025
